FDA calendar · May 2017 · built from SEC filings

PDUFA dates May 2017: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in May 2017. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in May 2017

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

May 2017: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
May 1, 2017Imfinzi® (durvalumab)AZNFDA approval—ApprovedopenFDA Drugs@FDA
May 4, 2017Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate)NVSFDA approval—ApprovedopenFDA Drugs@FDA
May 5, 2017Imvexxy (estradiol)TXMDComplete Response Letter—CRL issuedFDA Complete Response Letters
May 18, 2017Jadenu (deferasirox)NVSFDA approval—ApprovedopenFDA Drugs@FDA
May 22, 2017Kevzara (sarilumab)SNYFDA approval—ApprovedopenFDA Drugs@FDA

May 2017: dated readouts

No events in this view.

Questions

What PDUFA dates are in May 2017?

0 PDUFA dates fell in May 2017. The FDA calendar also recorded 5 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.